2^nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry May 30-31, 2019 | Orlando, Florida, USA

Helieh Oz has a DVM, MS (U. IL); Ph.D. (U. MN) and clinical translational research certificate. She is an active member of the American Association of Gastroenterology (AGA) and AGA Fellow and Associate in Rome Foundation (Functional Gastrointestinal Diseases). She is Microbiologist: expertise in infectious and  inflammatory diseases, drug discoveries, pathogenesis, innate/mucosal Immunity, molecular biology, and micronutrient. She has over 90 publications, books and book chapters in the areas of chronic inflammatory disorders (pancreatitis, hepatitis, colitis), microbial and infectious diseases. She serves as Lead/ co-editor for current special issues “Chronic Inflammatory and Infectious Diseases” (Diseases), “EGCG, Polyphenols” (Molecules), “Interactions between diets, gut microbiota and host metabolism” (Frontiers Microbiology), as well as previous issues “Gut inflammatory, infectious diseases, nutrition; Gastrointestinal inflammation, repair: role of microbiome, infection”, J Nutrient, guest-Editor “J. Pediatric Infectious Disease.” She is a member of different editorial board and an avid reviewer for journals. 

Alexander Fleming (1929) accidentally discovered antimicrobial effects of Penicillium mold which led to developments of modern medicine. Ever since antibiotics have become the cornerstone to fight pathogens and infectious diseases. Yet, with the advent of antibiotics resistance microbial, hospital-acquired infections, as well as emerge of the superbugs, have altered several clinical presentations and therapeutic approaches. As an example, sepsis and septic shock syndrome are the leading causes of death in critically ill patients and claiming over ¼ of million deaths annually in the United States alone. Microbial endotoxemia plays a key role in sepsis, released by colonic microorganisms. The incidence of sepsis in intensive care patients has been increasing. Recent years, the primary admission of elderly patients with cardiovascular disease (coronary artery disease and congestive heart failure) has been declining compared to escalating infectious diseases with explicitly labeled sepsis. Mycobacterium tuberculosis epidemic (TB) silently infects 1/3rd of the global population and is responsible for the death of almost 2 million people. In China, 1 million people develop the disease each year and about 100,000 become multi-drug resistance TB. This interactive presentation will aim to discuss antibiotics in health and in disease. In addition, possible preventive measures will be scrutinized. 

Statement of the Problem: Lactobacilli are live microorganisms which, when administered in adequate amounts, confer a health benefit on the host. Lactobacilli are commonly delivered in the food system. However, when these microorganisms are ingested, their activity and viability are reduced under highly acidic conditions of the stomach. In addition, the usual starter organisms in yogurt are not bile-tolerant and do not colonize the intestines. Hence, there is a need for Lactobacilli products that are resistant to the stressful conditions of the stomach and the upper intestine. Secondly, the viability of Lactobacilli in the product and the stability under different storage conditions has received very little attention. Thus, the objective of this study was to formulate and characterize gastro resistant Lactobacilli microspheres. Methodology and Theoretical Orientation: Hydroxyl Propyl Methyl Cellulose Acetate Succinate (HPMCAS), Ethyl cellulose (EC) and Bovine Serum Albumin (BSA) were used as the polymer matrix to make Lactobacilli microspheres. These microspheres were then characterized using several instruments and techniques in order to determine the physical and chemical properties of the microspheres. Findings and Conclusion: The product yield and the encapsulation efficiency were 45% and 100% respectively. No Lactobacilli were released from the Lactobacilli microspheres for the first 3hours in acidic media when the microspheres are supposed to be in the stomach. However, the Lactobacilli microspheres showed the highest release at 4hours, when they are supposed to be in the intestine that is the target site. The average microsphere particle size was 5μm. Lactobacilli microspheres proved to be most stable when stored at 40oC and showed a better suspendibility in distilled water compared to that in buffers. The viability studies showed that the Lactobacilli are most stable in encapsulated form (i.e. Lactobacilli microsphere form) in acidic conditions of the stomach compared to the unencapsulated form, which dies in the acidic conditions of the stomach. 

Problem Statement: Medical conditions that are fully or partially irremediable, and which have the potential to leave patients permanently debilitated, are prevalent, despite the wide clinical availability of therapeutics, drugs, and diagnostic tools. Major contemporary health and well-being risks are onsets by a slew of causative agents, including antibiotic-resistant microorganisms that prompt facilely transmissible infectious diseases; inherited genetic disorders or mutations that maximize the likelihood of certain cancers in affected individuals; and traumatic injuries that result in lifelong localized pain, disfigurement, or surgical intervention. Methodology: Nanotechnological solutions are dependent on the manipulation of elementary constituents to produce particles or features with dimensions on the order of 100nm or less, from extremity-to-extremity, and which display optimal quantum effects and enhanced surface area to volume ratios. Facile synthesis approaches, including nanoparticle self-assembly, hydrothermal production, and biogenic methods, have been adapted to achieve these Nano dimensions in medical systems.

Findings: Unique nanoparticle physiochemical properties, pertaining to size, morphology, and electronic responsiveness contribute to biomolecular impairment and ATP depletion in antagonistic cell types. For instance, noble metal and metal oxide nanoparticles have demonstrated anti-bacterial and anti-cancer efficacy following their application within in-vitro and in-vivo environments. Targeted delivery has been successfully approached through the synthesis of nanocarriers loaded with various drugs, proteins, genetic materials, and fluorescent probes. Nanofibrous or nano featured orthopedic scaffolds with optimal surface energies and mechanical properties have aided in implant optimization. 

Conclusions: Advances in nanotechnology will produce an index of safe and versatile treatments that functionally exceed current regimens or that warrant clinical solutions to otherwise untreatable medical complications or conditions.